Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
19.57
Price to sales ratio
3.2

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
820
ELAN
Elanco Animal Health Incorporated Common Stock
24.51 USD-2.23%+3.46%-4.67%+9.44%12.25 B USD
918
RDY
Dr. Reddy's Laboratories Ltd
12.15 USD-0.57%+0.16%+3.23%-14.07%10.14 B USD
1164
LNTH
Lantheus Holdings, Inc. - Common Stock
100.47 USD-0.35%+0.03%-0.82%+79.22%6.56 B USD
1258
AMRX
Amneal Pharmaceuticals, Inc. - Class A Common Stock
18.01 USD+0.11%+0.11%-4.71%+70.71%5.75 B USD

Frequently asked questions about Alkermes Inc. plc

What is the Alkermes Inc. plc stock price today?

The current price of Alkermes Inc. plc (ALKS) is 48.9. Over the past 24 hours, the stock has changed by -0.53%. Follow the ALKS chart for real-time price dynamics.

What is the stock ticker of Alkermes Inc. plc?

Alkermes Inc. plc trades under the ticker ALKS. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Alkermes Inc. plc stock going up?

ALKS has changed by +1.77% over the last week, -3.17% over the last month, and +68.74% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Alkermes Inc. plc?

Alkermes Inc. plc currently has a market capitalization of 8.2 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Alkermes Inc. plc earnings last quarter?

Last quarter, Alkermes Inc. plc reported earnings of 0 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Alkermes Inc. plc revenue for the last quarter?

Alkermes Inc. plc reported quarterly revenue of 496.01 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Alkermes Inc. plc net income for the last quarter?

Alkermes Inc. plc reported net income of 501 K for the last quarter. The previous quarter showed -66.48 M, which means net income changed by +100.75%.

How many employees does Alkermes Inc. plc have?

As of the latest available data, Alkermes Inc. plc has 2 050 employees. Workforce size can provide additional context about the company's scale and operations.

What is Alkermes Inc. plc EBITDA?

Alkermes Inc. plc EBITDA is 48.63 M, and its EBITDA margin is 9.8%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Alkermes Inc. plc stock?

You can buy Alkermes Inc. plc (ALKS) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Alkermes Inc. plc stock?

Investing in Alkermes Inc. plc requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the ALKS chart and related analysis on metatrader.com as part of your research.

Alkermes plc - Ordinary Shares

Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.

News